A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Female cancer patients have a 21% lower risk of death than men across 12 different types of advanced cancers, researchers recently reported in the Journal of the National Cancer Institute.

Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings ...

Compounds found in cannabis could provide a new roadmap for treating the world’s most common chronic liver disorder, according to a study released by the Hebrew University of Jerusalem.

The prescription drug leucovorin is getting a label update, though it’s not what that the US Food and Drug Administration ...

MIRA Pharmaceuticals has completed dosing in its Phase I clinical trial of Ketamir-2, the company’s selective oral N-methyl-D-aspartate (NMDA) receptor modulator, assessing its safety, tolerability, ...

Ovarian cancer (OC) is a "silent killer" with an annual incidence of 11.2 per 100,000 and mortality of 7.6 per 100,000. Most cases are diagnosed at ...

Ifenyinwa Chizube Ndulue-Nonso was hired as a dietician at Manchester Royal Infirmary in 2024. Having moved from Nigeria, she claimed to have experience working with a range of different health ...

Engineers at the University of Pennsylvania have built a lipid nanoparticle that chemically fuses an IDO-pathway inhibitor with the very lipids that carry IL-12 mRNA into tumors, creating a single ...